157 related articles for article (PubMed ID: 38062011)
41. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
42. BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways.
Zhang Y; Xu B; Shi J; Li J; Lu X; Xu L; Yang H; Hamad N; Wang C; Napier D; He S; Liu C; Liu Z; Qian H; Chen L; Wei X; Zheng X; Huang JA; Thibault O; Craven R; Wei D; Pan Y; Zhou BP; Wu Y; Yang XH
Cell Oncol (Dordr); 2020 Dec; 43(6):1049-1066. PubMed ID: 33006750
[TBL] [Abstract][Full Text] [Related]
43. The oncogenic transcription factor FOXQ1 is a differential regulator of Wnt target genes.
Pizzolato G; Moparthi L; Söderholm S; Cantù C; Koch S
J Cell Sci; 2022 Oct; 135(19):. PubMed ID: 36124643
[TBL] [Abstract][Full Text] [Related]
44. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
45. STAT3-induced NCK1 elevation promotes migration of triple-negative breast cancer cells via regulating ERK1/2 signaling.
He P; Sheng J; Qi J; Bai X; Li J; Wang F; Yuan Y; Zheng X
Mol Biol Rep; 2022 Jan; 49(1):267-278. PubMed ID: 34846647
[TBL] [Abstract][Full Text] [Related]
46. Activating Transcription Factor 4 Modulates TGFβ-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
González-González A; Muñoz-Muela E; Marchal JA; Cara FE; Molina MP; Cruz-Lozano M; Jiménez G; Verma A; Ramírez A; Qian W; Chen W; Kozielski AJ; Elemento O; Martín-Salvago MD; Luque RJ; Rosa-Garrido C; Landeira D; Quintana-Romero M; Rosato RR; García MA; Ramirez-Tortosa CL; Kim H; Rodriguez-Aguayo C; Lopez-Berestein G; Sood AK; Lorente JA; Sánchez-Rovira P; Chang JC; Granados-Principal S
Clin Cancer Res; 2018 Nov; 24(22):5697-5709. PubMed ID: 30012564
[No Abstract] [Full Text] [Related]
47. SMC1 promotes epithelial-mesenchymal transition in triple-negative breast cancer through upregulating Brachyury.
Li K; Ying M; Feng D; Chen Y; Wang J; Wang Y
Oncol Rep; 2016 Apr; 35(4):2405-12. PubMed ID: 26781859
[TBL] [Abstract][Full Text] [Related]
48. Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2/AKT/β-catenin signaling.
Chen X; Yang M; Yin J; Li P; Zeng S; Zheng G; He Z; Liu H; Wang Q; Zhang F; Chen D
Cell Commun Signal; 2022 Jun; 20(1):92. PubMed ID: 35715860
[TBL] [Abstract][Full Text] [Related]
49. SIRT1 induces tumor invasion by targeting epithelial mesenchymal transition-related pathway and is a prognostic marker in triple negative breast cancer.
Jin MS; Hyun CL; Park IA; Kim JY; Chung YR; Im SA; Lee KH; Moon HG; Ryu HS
Tumour Biol; 2016 Apr; 37(4):4743-53. PubMed ID: 26515337
[TBL] [Abstract][Full Text] [Related]
50. Reciprocal transrepression between FOXF2 and FOXQ1 controls basal-like breast cancer aggressiveness.
Kang LJ; Yu ZH; Cai J; He R; Lu JT; Hou C; Wang QS; Li XQ; Zhang R; Feng YM
FASEB J; 2019 May; 33(5):6564-6573. PubMed ID: 30807702
[TBL] [Abstract][Full Text] [Related]
51. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition.
Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y
Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968
[TBL] [Abstract][Full Text] [Related]
52. Potentiation of cancerous progression by LISCH7 via direct stimulation of TGFB1 transcription in triple-negative breast cancer.
Tang X; Zhou Y; Liu Y; Zhang W; Liu C; Yan C
J Cell Biochem; 2020 Nov; 121(11):4642-4653. PubMed ID: 32048750
[TBL] [Abstract][Full Text] [Related]
53. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
54. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
55. miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.
Wang Z; Wang X
J Cell Physiol; 2020 Mar; 235(3):2825-2835. PubMed ID: 31541468
[TBL] [Abstract][Full Text] [Related]
56. Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.
Yue CH; Liu JY; Chi CS; Hu CW; Tan KT; Huang FM; Pan YR; Lin KI; Lee CJ
Anticancer Res; 2019 Aug; 39(8):4149-4164. PubMed ID: 31366500
[TBL] [Abstract][Full Text] [Related]
57. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
58. Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.
Feng J; Xu L; Ni S; Gu J; Zhu H; Wang H; Zhang S; Zhang W; Huang J
Oncotarget; 2014 Oct; 5(20):9689-702. PubMed ID: 25356753
[TBL] [Abstract][Full Text] [Related]
59. SNAI1-mediated transcriptional regulation of epithelial-to-mesenchymal transition genes in breast cancer stem cells.
Singh D; Deshmukh RK; Das A
Cell Signal; 2021 Nov; 87():110151. PubMed ID: 34537302
[TBL] [Abstract][Full Text] [Related]
60. FRZB is Regulated by the Transcription Factor EGR1 and Inhibits the Growth and Invasion of Triple-Negative Breast Cancer Cells by Regulating the JAK/STAT3 Pathway.
Liu H; Mei Y; Ma X; Zhang X; Nie W
Clin Breast Cancer; 2022 Oct; 22(7):690-698. PubMed ID: 35787980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]